Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases

Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases

Copyright © 2018. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 194(2018) vom: 15. Sept., Seite 75-79
1. Verfasser: Espinosa, Eric (VerfasserIn)
Weitere Verfasser: Valitutti, Salvatore, Laroche, Michel, Laurent, Camille, Apoil, Pol André, Hermine, Olivier, Lavit, Michel, Paul, Carle, Bulai Livideanu, Cristina
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Hydroxychloroquine Mast cell activation diseases Mast cell activation syndrome Mast cells Mastocytosis Inflammation Mediators 4QWG6N8QKH
Beschreibung
Zusammenfassung:Copyright © 2018. Published by Elsevier Inc.
There is no therapeutic agent approved in cutaneous mastocytosis and mast cell activation syndrome. We report the efficacy of hydroxychloroquine in four patients with cutaneous mastocytosis (n = 2) and mast cell activation syndrome (n = 2). We show that this molecule reduces the long-term survival of primary human mast cells, interferes with lysosome function and leads to the accumulation of non-functional tryptase in the mast cell granules. Furthermore, hydroxychloroquine decreases the production of pro-inflammatory mediators
Beschreibung:Date Completed 14.08.2019
Date Revised 14.08.2019
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2018.07.004